Throughout the COVID-19 pandemic, government policy and healthcare implementation responses have been guided by reported positivity rates and vaccination rates in the community. The selection bias of these test data questions their validity as measures of the actual viral incidence in the community and as predictors of clinical burden. Publicly available vaccination data are frequently cited as a proxy for population immunity, but this metric ignores the effects of naturally-acquired immunity. The health disparities concerning asymptomatic and symptomatic patients are not yet studied. The proposal develops a valid metric to estimate the true viral incidence and naturally/vaccine-acquired immunity prevalence in the community, examine the health disparities and social inequality, and monitor the epidemic over time as an operational surveillance system. The approach collects routine testing data on SARS-CoV-2 exposure and antibody seropositivity among patients in a hospital system and performs statistical adjustments of sample representation using multilevel regression and poststratification (MRP), which adjusts for measured differences between the sample and population and also yields stable small area estimates. The data collection and analysis procedure can provide information to entire communities with generalizability and focus on burdens within specific demographics, with close attention to vulnerable populations on disparities across health outcomes, social determinants, and behaviors. In particular, the research will yield group-specific estimates of disparities with respect to asymptomatic and symptomatic patients and how these discrepancies may impact the socio-demographically dependent spread of disease and its subsequent treatment. The MRP adjustment will be made publicly accessible via a web interface and promote broad investigations with integrated data sources toward a national study.
Health and Human Services, Department of-National Institutes of Health
04/01/2022 to 12/31/2025